Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant HAIC plus donafenib after hepatectomy for high-risk hepatocellular carcinoma
ChiCTR2100045770Phase 2Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- May 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of donafenib and durvalumab + lenvatinib + gemcitabine + cisplatin in hepatocellular carcinoma (HCC), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: 2-year cumulative recurrence-free survival rate. Started May 2021; status: recruiting.
02
Drugs
donafenibdurvalumab + lenvatinib + gemcitabine + cisplatin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2100045770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045770.